<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background/Aims: Cetuximab is currently approved for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCR) with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Prior few studies demonstrated that G13D mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> could benefit from cetuximab </plain></SENT>
<SENT sid="2" pm="."><plain>This study aims to investigate whether KRAS G13D mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> benefit from cetuximab in the chemotherapy refractory patients </plain></SENT>
<SENT sid="3" pm="."><plain>Methodology: We retrospectively compared progression-free survival (PFS), overall survival (OS) and response rate (RR) according to KRAS mutation status in 105 patients with mRC treated at the Cerrahpasa Medical School Hospital, between October 2008 and October 2011, with cetuximab alone or in combination with chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Results: PFS was significantly longer in patients G13D mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (6.81 months) than in patients with other KRAS mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (5 months) (p=0.027) </plain></SENT>
<SENT sid="5" pm="."><plain>No significant difference in PFS between patients G13D mutated and KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was detected </plain></SENT>
<SENT sid="6" pm="."><plain>No significant difference in OS was detected in patients between G13D mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and other KRAS mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>However, patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had significantly longer OS (16.1 months) than patients with mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (8.9 months) (p=0.025) </plain></SENT>
<SENT sid="8" pm="."><plain>RR in patients with other KRAS mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, was significantly worse than those with G13D mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (p=0.002) </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusion: Our study demonstrated an association between the presence KRAS G13D mutanted and survival chemotherapy in refractory <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> treated with cetuximab </plain></SENT>
</text></document>